This content is machine translated Non-resectable melanoma New triple therapy improves progression-free survival Both protein kinase inhibitors and ipilimumab/nivolumab combined have better efficacy than their respective monotherapies in patients with non-resectable melanoma. This has been known for some time. An interesting new approach…
View Post 4 min This content is machine translated 28th German Skin Cancer Congress 2018, Stuttgart Update on immunotherapy of malignant melanoma Combination immunotherapy, adjuvant immune checkpoint blockade, and long-term survival after PD-1 inhibitor therapy were the topics of two satellite symposia at the German Skin Cancer Congress.
View Post 6 min This content is machine translated ESMO 2017 in Madrid Blocking the “escape route” for the tumor Upsets in first-line therapy of non-small cell EGFR-mutated lung cancer are imminent. With the FLAURA trial, osimertinib is confidently presenting itself for the first time as a treatment option for…
View Post 15 min This content is machine translated Focus - Skin Cancer Malignant Melanoma, Targeted Therapy and Immunotherapy – The Road to Success Thanks to the approval of new therapeutic approaches, the treatment of advanced melanoma has been further developed in recent years. Patients with metastatic melanoma who undergo immunotherapy and/or targeted therapy…
View Post 4 min This content is machine translated Immuno-Oncology New pathways for improved cancer treatment? Long-term survival of patients with advanced-stage carcinoma is still an area where research is far from successful. In the field of melanoma, the approval of ipilimumab in 2011 has made…
View Post 8 min This content is machine translated New therapies Progress in metastatic malignant melanoma New insights in tumor biology and immunology as well as in molecular pathology have rapidly driven the development of immunomodulatory antibodies and so-called “targeted” therapeutics [1]. This makes the therapy…
View Post 3 min This content is machine translated News on melanoma therapy at ASCO 2014 How do immunotherapies work in combination and in the adjuvant setting? In the course of this year’s ASCO congress in Chicago at the beginning of June, new results of the phase Ib study on the combination of PD1 and CTLA4 inhibition…
View Post 5 min This content is machine translated Early detection begins in the family doctor's office Melanocytic nevi and malignant melanoma Melanocytic nevi are the most common benign neoplasms in fair skin types. Their number is a risk indicator for the development of malignant melanoma, of which they may be precursors.…
View Post 4 min This content is machine translated ASCO Congress What is the potential of adjuvant therapy and genetic analysis? Current research desiderata on melanoma were presented at this year’s ASCO Congress. Immunotherapy is considered the basis of today’s adjuvant treatment, as radiotherapy is no longer recommended due to too…
